RECOMBINANT ANTIGEN FOR DIAGNOSIS AND PREVENTION OF MURINE TYPHUS

Abstract

The invention relates to a recombinant immunogenic composition from Rickettsia typhi. The invention also relates to a method for the use of the recombinant proteins in detection and diagnostic assays and as a component in formulations for the induction of an anti-R. typhi immune response.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation in part of application Ser. No. 11/789,122 filed Apr. 18, 2007 and is hereby incorporated by reference application Ser. No. 11/789,122 claims priority to U.S. Provisional application 60/793,583 filed Apr. 20, 2006.

SEQUENCE LISTING

[0002] I hereby state that the information recorded in computer readable form is identical to the written sequence listing.

BACKGROUND OF THE INVENTION

[0003] 1. Field of the Invention

[0004] This invention relates to a gene and protein which can be used for vaccination against and/or for the detection and identification of R. typhi infection. More particularly, the invention relates to a specific nucleotide sequence encoding a highly specific and immunogenic portion of the gene encoding the protective OmpB antigen of Rickettsia typhi and the polypeptide products of this gene. The polypeptide sequence can be utilized in diagnostic and detection assays for murine typhus and as an immunogen useful as a component in vaccine formulations against murine typhus.

[0005] 2. Description of the Prior Art

[0006] Murine (endemic or flea-borne) typhus, caused by infection with Rickettsia typhi, is a zoonosis that involves rats (Rattus rattus and R. norvegicus) as the main reservoir and the oriental rat flea (Xenopsylla cheopis) as the main vector [1,2]. The infection is primarily caused by scratching the flea bitted site and self-inoculating the R. typhi-laden feces, or directly by infected flea bite [3]. The symptoms of murine typhus include fever, headache, enlarged local lymph nodes and rashes on the trunk. These clinical manifestations are non-specific and resemble many other diseases such as viral infections, typhoid fever, leptospirosis, epidemic typhus and scrub typhus [3,10]. As a result, murine typhus is frequently misdiagnosed and its incidence is probably grossly underestimated.

[0007] Murine typhus is one of the most widely distributed arthropod-borne diseases of humans and occurs in a variety of environments from hot and humid lowlands to semi-arid highlands including Australia [6], Spain [7], Indonesia [8], and southwestern United States [9] in addition to previously reported countries including China, Thailand, Kuwait, Israel, and Vietnam [3,5]. It is often found in international port cities and costal regions where rodents are common [3-5].

[0008] The diagnosis of murine typhus relies mainly on serological methods [11]. The old serological assay, Weil-Felix test, is based on the detection of antibodies to Proteus vulgaris OX-19 that contains cross reactive epitopes of Rickettsia [12, 13]. However, determination of R. typhi infection by the Weil-Felix test requires a qualitative determination and therefore somewhat subjective. Additionally, because the Weil-Felix reaction requires specialized reagents, many facilities especially in rural areas or in developing countries often may not be capable of performing the laboratory diagnosis.

[0009] Other techniques include immuno-fluorescence assay (IFA) and complement fixation (CT) tests were adapted for the detection of antibodies specific for rickettsiae [14-16]. Current serodiagnostic assays such as the ELISA, Dip-S-Ticks (DS), indirect immunofluorescent antibody (IFA) and indirect peroxidase assays [17,18] require the propagation of rickettsiae in infected yolk sacs of embryonated chicken eggs or cell cultures to prepare the antigens used in these assays. However, only a few specialized laboratories have the ability to culture and purify rickettsiae, which requires Biosafety level three (BSL-3) containment facilities. Additionally, because the organism is required for the assay, in addition to potential biosafety hazards associated with the assay, these assay methods also suffer from refrigerated storage requirements, and the problem of reproducibility associated with frequent production of rickettsial antigens.

[0010] In addition to antibody-based assays, polymerase chain reaction (PCR) amplification of rickettsial protein antigen genes has been demonstrated as a reliable diagnostic method, and genotypes can be determined without isolation of the organism [19,20]. However, gene amplification requires sophisticated instrumentation and reagents generally not available in most medical facilities especially those far forward. Based on these considerations, production of recombinant antigens of R. typhi is a logic direction for the development of serological assays and vaccine candidates for murine typhus.

[0011] R. typhi has a monomolecular layer of protein arranged in a periodic tetragonal array on its surface [21]. This crystalline layer, representing 10 to 15% of the total protein mass of the rickettsia, was identified as the immunodominant species-specific surface protein antigen OmpB. It has been isolated, purified, and biochemically characterized [22-25]. The earliest and dominant immunological responses in mice, guinea pigs, rabbits, and humans, following infection with R. typhi, are directed against Omp B [17, 4, 25]. We have shown that purified native typhus OmpB induces strong humoral and cell mediated immune responses. Protective immunity was elicited by typhus OmpB in guinea pig and mouse protection models [26-29].

[0012] Based on these observations, therefore, OmpB is a particularly advantageous target for developing diagnostic reagents. R. prowazekii, the etiologic agent of epidemic typhus, also belongs to the typhus group of rickettsiae and its OmpB exhibits similar antigenic and chemical structures to those of R. typhi. Therefore, cross-reactivity of antibody to OmpB between these two species is inevitable. Cross absorption of test serum is needed to distinguish between them these to species [10].

[0013] The whole ORF of OmpB codes for a polypeptide of 1642 amino acids. The native matured protein does not contain the leader peptide at the N-terminus and the β-sheet peptide at the C-terminus. The expression of the intact OmpB protein (135 kDa) has been attempted. However, the full-length product was shown to be toxic to Escherichia coli and rapidly degraded. Moreover, due to its large size and high constant of β-sheet structure, refolding of the full-length gene product was not successful.

SUMMARY OF THE INVENTION

[0014] Accordingly, an object of this invention are methylated and unmethylated recombinant polypeptides encompassing immunologically active regions of OmpB of Rickettsia typhi.

[0015] Another object of the invention is a method of using the methylated or unmethylated recombinant OmpB fragments in antibody-based assays for the detection of exposure to Rickettsia typhi.

[0016] A still further object of the invention is the use of OmpB or the OmpB fragments as an immunogen.

BRIEF DESCRIPTION OF DRAWINGS

[0017] FIG. 1. Open reading frame of OmpB and location of Fragments A, K and AN.

[0018] FIG. 2. Western blot analysis of IgG and IgM reactivity to fragment AN.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Evaluation of Rickettsia typhi proteins has led to the identification of OmpB is an exceptionally promising candidate as a reagent for use in diagnostic and detection assays as well as components in vaccine formulations. The species-specific surface protein antigen OmpB (SEQ ID No. 3, encoded by nucleotide sequence of SEQ ID No. 4) of R. typhi was identified as the immunodominant. The earliest and dominant immunological anti-protein responses of mice, guinea pigs, rabbits, and humans following infection with R. typhi are directed against this Omp B antigen. These observations suggested OmpB as an appropriate target for developing diagnostic reagents.

[0020] Central to the development of improved detection and diagnostic immunoassay methods and standardization is the development of more effective antigens for use in existing antibody-based methods. In order to improve the antigenicity and potential immunogenicity of the OmpB, specific regions of OmpB were evaluated for sera reactivity. Western blot analysis of partially digested OmpB revealed that all the reactive fragments were larger than 20 kDa [31]. One reactive fragment was located at the N-terminus and another located at the C-terminus. Along these lines, efforts have been made to identify immunodominant fragments of OmpB proteins. Accordingly, two highly sera-reactive protein fragments (Fragment A and Fragment K) have been identified. FIG. 1 illustrates the location of these fragments within the OmpB molecule. The location Fragment AN, which has the amino acid sequence of SEQ ID No. 1 and is encoded by nucleotide sequence SEQ ID No. 2, is also illustrated in FIG. 1.

[0021] Fragment AN was successfully cloned, expressed, purified, and refolded. The fragment has been shown to be recognized by different patient sera and can be used to replace whole cell antigens and/or native OmpB as a diagnostic marker and a potential vaccine candidate.

[0022] Construction of recombinant R. typhi protein AN Fragment was carried out by first producing a cDNA copy of the gene sequence by polymerase chain reaction. A primer pair (SEQ ID No. 5 and 6) was designed using the nucleotide sequence of the ORF of R. typhi OmpB.

[0023] The coding sequence was amplified by PCR using DNA from R. typhi Wilminton strain. Amplification was conducted in a mixture of 400 mM each of deoxynucleotide triphosphate, 1 μM of each primer, 1.5 U of Taq polymerase (Perkin Elmer-Cetus, Norwalk Conn.) in 10 mM Tris-HCl buffer, pH 8.3, 1.5 mM MgCl₂, and 50 mM KCl. The PCR reaction was started with 5 min at 94 C, and followed by 30 cycle of 94 C for 50 second, 55 C for 1 min and 72 C for 2 min. the last cycle was extended for 10 min at 72 C. the amplified gene fragment was digested with Nde I (New England BioLabs, Beverly, Mass.) and BamHI (GIBCO-BRL Life Technology, Gaithersburg, Md.) and ligated with doubly digested expression vector pET28a.

[0024] Fragment AN was expressed as inclusion body in E. coli BL21. The inclusion bodies were extracted with 0.1×BUG BUSTER® (Novagene (EMD), San Diego, Calif.) three times. The final pellet was dissolved in 8 M urea and purified over a nickel column then refolded by sequential dialysis in decreasing concentrations of urea. The chemical methylation of fragment A was performed according to the procedures described by Taralp and Kaplan (J. Prot. Chem. 16, 183-193, 1997).

[0025] Fragment K coding sequence from amino acid 745 to 1353 was amplified by PCR from DNA isolated R. typhi Wilminton strain. The fragment K gene was amplified in a 50 ul mixture of 150 mM each of deoxynucleotide triphosephate, 0.8 μM of each primer, 2.5 U of Taq Gold polymerase (Perkin Elmer-Cetus, Norwalk Conn.) in 10 mM Tris-HCl buffer, pH 8.3, 1.5 mM MgCl₂, and 50 mM KCl. The PCR reaction was started with 10 min at 94 C, and followed by 30 cycle of 94 C for 30 second, 55 C for 30 second and 72 C for 2 min. the last cycle was extended for 7 min at 72 C. The ligation of the amplified fragment K in to pET11a was the same as for fragment A.

[0026] Fragment K was over-expressed in BL21 cells by induction with 1 mM IPTG for 4 hr. The over-expressed K was primarily in the inclusion body and was extracted with 4 M urea. The solubilized K in 4 M urea was further purified with HPLC using two gel filtration columns in tandem (TSK-G3000-SW and TSK-G4000-SW) followed by an anion exchange column using a NaCl gradient (50-100 mM in 30 minutes). A greater than 95% purity as demonstrated by SDS-PAGE. The purified K was refolded by dialysis in 2 M urea at 4° C. with two changes of dialysis solution in the presence of reduced glutathione (1 mM), followed by dialysis in buffer without urea. Expression of Fragment AN was accomplished by inserting the encoding DNA into a suitable expression system, such as pET 28a. The R. typhi recombinant protein antigen can be utilized as an antigen either as an unpurified E. coli lysate or purified by any number of methods and subsequently used as antigen in detection or diagnostic assays.

[0027] Table 1 illustrates the immuno-reactivity of fragment AN from Richettsia typhi in enzyme-linked immunosorbent assay (ELISA). Serum from R. typhi exposed patients were reacted to either fragment AN or whole cell. As shown in Table 1, serum antibodies that did not exhibit sero-reactivity to whole cell antigen also did not react to fragment AN. However, sera positive to whole cell antigen was also reactive to fragment AN. In Table 1, "0" indicates negative titer and therefore negative serum reactivity.

TABLE-US-00001 TABLE 1 Antibody reacitivty against fragment AN or whole cell antigen in ELISA ELISA (ANt) ELISA (whole cell) Serum O.D. titer 65 0.481 + 1/100 107 0.313 + 1/100 113 0.456 + 1/100 163 0.255 - 0 186 0.227 - 0 219 0.161 - 0 224 0.411 + 1/400 243 0.368 + 1/100 245 0.458 + 1/100 250 0.206 - 0 255 0.386 + 1/100 256 0.333 + 1/100 278 0.195 - 0 319 0.071 - 0 376 0.922 + 1/400 453 0.14 - 0 459 0.221 - 0 527 0.08 - 0

[0028] FIG. 2 further illustrates the immunogenicity and immune reactivity of fragment AN. FIG. 2 shows western blot analysis of AN or OmpB against either negative or serum from patients previously exposed to R. typhi. In FIG. 2, OmpBt is the native antigen OmpB of R. typhi and serves as the positive control for the sero-reactivity of recombinant antigen AN. As illustrated in the figure, both IgG as well as IgM antibody isotypes were highly reactive to fragment AN.

[0029] Based on these results, protein fragment AN will be a valuable antigen in detection and diagnostic assays either alone or in assays incorporating other R. typhi recombinant proteins, for example Fragment K (SEQ ID. No. 8). Standardization of antigen will improve assay diagnostic performance and provide early and more accurate treatment regimens. Improved sensitivity can be achieved by combination of protein fragments containing a greater number of epitopes well represented in serum antibody repertoires.

[0030] Accordingly, an aspect of this invention is the recombinant expression of an immunodominant fragment, fragment AN, derived from the outer membrane protein OmpB. This recombinant protein fragment can be used as antigen in a method for the detection of R. typhi infection and murine typhus. Recombinant versese whole cell antigen will confer improved standardization and concomitant assay reproducibility and potentially sensitivity in assays for the detection and diagnostic assays.

[0031] The following examples are provided to further illustrate the use of the invention.

Example 1

Use of OmpB fragment AN as Diagnostic Reagent

[0032] Assays using the recombinantly produced proteins include antibody-based assays such as enzyme-linked immunosorbent assays. As previously mentioned, antigen for the assay can be in the form of unpurified E. coli lysate. However, for increased assay sensitivity and reduced background, purified recombinant R. typhi proteins can be used. The general method is to use the recombinant polypeptide as antigen in order to detect anti-R. typhi antibodies. As such, recombinant AN polypeptide, or AN fragments containing B cell epitopes, is exposed to patient antibody. Antibody binding is, therefore, detected by any number of means including enzyme-linked immunosorbant assay, indirect florescent assay (i.e., IFA), plasmon resonance or of a number of other means for detecting antigen-antibody interaction. Additionally, for increased accuracy of the assay, AN, or fragments thereof can be used in tandem with other recombinant proteins such as OmpB, Fragments A or K.

[0033] Either the entire AN fragment or one or more fragments containing the predicted B-cell epitopes, contained in fragment AN, can be utilized. Table 2 illustrates predicted B-cell epitopes contained in fragment AN and are represented by SEQ ID No.s 9-29.

TABLE-US-00002 TABLE 2 Predicted B-cell epitopes contained in fragment AN Amino Acid Amino Acid position Sequence 4 VMQYNRTTNAA 40 ITANSNNAITFNTPNGNLNS 82 TNVTKQGN 111 QQAATTKSAQNV 131 AINDNDLSG 157 INPTTQEAP 187 GFVKVSDKTF 231 INFNGRDGTGKLVLVSKNGNATE 305 SVDNGNAAT 345 GGKTNFKTADSKV 390 IGDAKNNGNTAG 410 TLVSGNTDPN 464 NGPVNQNPLVNNNALA 542 IQLTSTQNNIL 558 DVTTDQTGV 570 SSLTNNQTLT 590 NTKTLGRFNVGSSKT 619 ENDGSVHLTHNTY 638 NAANQGK 650 DPINTDT 698 NNITTTDANVGSL

[0034] As an illustration, the following procedure is provided, comprising the following steps: [0035] 1. Recombinant protein represented by SEQ ID No. 1, or one or more fragments thereof, is immobilized to a solid surface, such as in 96-well plates; [0036] 2. Unreacted/unbound antigen is washed off. A preferred embodiment of the inventive method is to wash at least 3 times with wash buffer containing 0.1% polysorbate surfactant such as polyoxyethylene (20) sorbitan monolaurate; [0037] 3. Block unreacted sites. In a preferred embodiment, blocking of unreacted sites is accomplished with 5% skim milk in wash buffer) X 45 minutes and then rinsed three times. [0038] 4. React test sera to the bound antigen. As a further control, intact OmpB (SEQ ID No. 3), can also be immobilized and exposed to patient sera; [0039] 5. Plates are washed three times with wash buffer; [0040] 6. After incubating the test sera, the bound antibody-antigen is exposed to a probe. In a preferred embodiment, the probe is enzyme-labeled (e.g. peroxidase) anti-human immunoglobulin; [0041] 7. detecting bound probe. Detection of bound probe can by any number of methods. In a preferred embodiment, detection is by measurement of enzymatic reaction of added substrate.

[0042] The above specific procedural outline is provided to illustrate the general method of using the fragments for the detection R. typhi infection. However, other iterations of the general antibody-based procedure is contemplated. Furthermore, a standard curve can be constructed by conducting the above ELISA procedures with the recombinant proteins but utilizing a range of concentrations of specific antibody to R. typhi. The extent of measured binding of patient serum antibody is compared to a graphic representation of the binding of the R. typhi-specific antibody concentrations.

Example 2

Prophetic Use of Recombinant R. typhi Proteins as a Vaccine Component

[0043] Because of its strong immunoreactivity with serum antibody from R. typhi exposed patients, the recombinantly produced polypeptides is an excellent candidate for use as a componented in R. typhi vaccine formulations. Accordingly, Fragment AN (SEQ ID No. 1), or one or more fragments of the R. typhi protein Fragment AN or their respective DNA sequences (SEQ ID No. 2) incorporated into a suitable expression vector system, can be utilized as vaccine components. Fragments of AN containing B-cell epitopes are represented by SEQ ID No.s 9-29 (see also Table 2). The method for induction of R. typhi immunity contains the following steps: [0044] a. administering an immunogenic composition containing the entire or immunogenic fragments of the recombinant polypeptides selected from the group consisting of SEQ ID No. 1 in a unit dose range of 50 μg to 2 mg; [0045] b. administration of boosting dose of said immunogenic composition at least 1 week after priming dose with unit dose range of 50 μg to 2 mg in a buffered aqueous solution, wherein an immune response is elicited.

[0046] An alternative method of immunizing is to administer DNA sequences encoding Fragment AN, or combinations thereof, inserted into a suitable expression system capable of expressing the fragments in vivo. Suitable expression systems can include viral expression vectors as well as a number of available DNA vector systems.

REFERENCES

[0047] 1. Ito, S., J. W. Vinson & T. J. McGuire, Jr. 1975. Murine typhus Rickettsiae in the oriental rat flea. Ann. N.Y. Acad. Sci. 266: 35-60 [0048] 2. Farhang-Azad, A., R. Traub & C. L. Wisseman, Jr. 1983. Rickettsia mooseri infection in the fleas Leptopsylla segnis and Xenopsylla cheopis. Am. J. Trop. Med. Hyg. 32: 1392-1400 [0049] 3. Azad A F. Epidemiology of murine typhus. Annu Rev Entomol 1990; 35:553-69. [0050] 4. Kelly D J, Richards A L, Temenak J J, Stickman D, Dasch G A. The past and present threat of rickettsial diseases to military medicine and international public health. Clin Infect Dis 2002; 34 (suppl 4):s145-s169. [0051] 5. Traub, R., C. L. Wisseman & A. Farhang-Azad. 1978. The ecology of murine typhus--a critical review. Trop. Dis. Bull. 75: 237-317 [0052] 6. Jones, S L, Athan E, OquadratureBrien D, Graves S R, Ngyuyen C, Stenos J. Murine typhus: the first reported case from Victoria. Med. J. Aust. 2004 May 3; 180(9):482. [0053] 7. Lledo L, Gegundez I, Ruiz E, Rodriguez L, Bacellar F, Saz J V. Rickettsia typhi infection in wild rodents from central Spain. Ann Trop Med. Parasitol. 2003 June; 97(4):411-4. [0054] 8. Richards A L, Rahardjo E, Rusjdi A F, Kelly D J, Dasch G A, Church C J, Bangs M J. Evidence of Rickettsia typhi and the potential for murine typhus in Jayapura, Irian Jaya, Indonesia. Am J Trop Med. Hyg. 2002 April; 66(4):431-4. [0055] 9. Walker, D. H., F. M. Parks, T. G. Betz, et al. 1989. Histopathology and immunohistologic demonstration of the distribution of Rickettsia typhi in fatal murine typhus. Am. J. Clin. Pathol. 91: 720-724 [0056] 10. La Scola B, Rydkina L, Ndihokubwayo J B, Vene S, Raoult D. Serological differentiation of murine typhus and epidemic typhus using cross-adsorption and Western blotting. Clin Diagn Lab Immunol. 2000 July; 7(4):612-6. [0057] 11. La Scola B, Raoult D. Laboratory diagnosis of rickettsioses: current approaches to diagnosis of old and new rickettsial diseases. J Clin Microbiol. 1997 November; 35(11):2715-27. Review. [0058] 12. Weil E., and A. Felix. 1916. Zur serologischen Diagnose des Fleckfiebers. Wien. Klin. Wochenschr. 29:33-35. [0059] 13. Ormsbee R, Peacock M, Philip R, Casper E, Plorde J, Gabre-Kidan T, Wright L. Serologic diagnosis of epidemic typhus fever. Am J. Epidemiol. 1977 March; 105(3):261-71. [0060] 14. Shepard C C, Redus M A, Tzianabos T, Warfield D T. Recent experience with the complement fixation test in the laboratory diagnosis of rickettsial diseases in the United States. J Clin Microbiol. 1976 September; 4(3):277-83. [0061] 15. Philip, R N, Casper E A, Ormsbee R A, Peacock M G, Burgdorfer W. Microimmunofluorescence test for the serological study of Rocky mountain spotted fever and typhus. J. Clin Microbiol. 3:51-61. [0062] 16. Shirai A, Dietel J W, Osterman J V. Indirect hemagglutination test for human antibody to typhus and spotted fever group rickettsiae. J Clin Microbiol. 1975 November; 2(5):430-7. [0063] 17. Eremeeva, M E., N M. Balayeva, D. Raoult. Serological response of patients suffering from primary and recrudescent typhus: comparison of complement fixation reaction, Weil-Felix test, microimmunofluorescence, and immunoblotting. Clin. Diagn. Lab. Immunol. 1994, 1:318-324. [0064] 18. Kelly D J, Chan C T, Paxton H, et al. Comparative evaluation of a commercial enzyme immunoassay for the detection of human antibody to Rickettsia typhi. Clin Diagn Lab Immunol 1995; 2:356-60. [0065] 19. Jiang J, Temenak J J, Richards A L. Real-time PCR duplex assay for Rickettsia prowazekii and Borrelia recurrentis. Ann N Y Acad. Sci. 2003 June; 990:302-10. [0066] 20. Kodama K, Senba T, Yamauchi H, Chikahira Y, Katayama T, Furuya Y, Fujita H, Yamamoto S. Fulminant Japanese spotted fever definitively diagnosed by the polymerase chain reaction method. J Infect Chemother. 2002 September; 8(3):266-8. [0067] 21. Palmer, E L., M L. Martin, and L. Mallavia. Ultrastructure of the surface of Rickettsia prowazekii and Rickettsia akari. Appl. Microbiol. 1974, 28:713-716. [0068] 22. Ching, W M., M. Carl, and G A. Dasch. Mapping of monoclonal antibody binding sites on CNBr fragments of the S-Layer protein antigens of Rickettsia typhi and R. Prowazekii. Mol. Immunol. 1992, 29:95-105. [0069] 23. Ching, W M., G A. Dasch, M. Carl and M E. Dobson. Structural analyses of the 120 Kda serotyupe protein antigens (SPAS) of typhus group rickettsiae: comparison with other S-layer proteins. Anna. N.Y. Acad. Sci. 1990, 590:334-351. [0070] 24. Dasch, G A. Isolation of species-specific protein antigens of Rickettsia typhi and Rickettsia prowazekii for immunodiagnosis and immnuoprophylzxis. J. Clin. Microbiol. 1981, 14:333-341. [0071] 25. Dasch. G A., J R. Samms, and J C. Williams. Partial purification and characterization of the major species-specific protein antigens of Rickettsia typhi and rickettsia prowazekii identified by rocket immunoelectrophoresis. Infect. Immun. 1981, 31:276-288. [0072] 26. Bourgeois, A L., and G A. Dasch. The species-specific surface protein antigens of Rickettsia typhi: immunogenicity and protective efficacy in guinea pigs. P. 71-80. In W. Burgdorfer and R L. Anacker (ed), Rickettsia and rickettsial diseases. Academic Press, New York. [0073] 27. Carl. M., and G A. Dasch. The importance of crystalline surface layer protein antigens of rickettsiae in T cell immunity. J. Autoimmun, 1989, 2:81-91. [0074] 28. Dasch, G A., and A L. Bourgeois. Antigens of the typhus group of rickettsiae: importance of the species-specific surface protein antigens in eliciting immunity, p 61-70. In W. Burgdorfer and R L. Anacker (ed), Rickettsia and rickettsial diseases. Academic Press, New York. [0075] 29. Dasch. G A., J P. Burans, M E. Dobson, F M. Rollwagen, and J. Misiti. Approaches to the subunit vaccines against the typhus rickettsiae, Rickettsia typhi and Rickettsia prowazekii, 251-256. In D. Schlessinger (ed), Microbiology-1984, American Society for Microbiology, Washington, D.C. [0076] 30. Ching, W M., H. Wang, J. Davis, and G A. Dasch. Amino acid analysis and multiple methylation of lysine residues in the surface protein antigen of Rickettsia prowazekii, p. 307-14. In R H. Angeletti (ed), Techniques in protein chemistry IV. Academic Press, San Diego. [0077] 31. Ching W M, Ni Y S, Kaplan H, Zhang Z, and Dasch G A (1997). Chemical methylation of E. coli expressed Rickettsia typhi protein increases its seroreactivity. Thirteenth Sesqui-Annual Meeting of American Society for Rickettsiology, Champion, Pa. abstract # 40. [0078] 32. Chao C C, Wu S L, and Ching W M. Using LC-MS with De novo Software to Fully Characterize the Multiple Methylations of Lysine Residues in a Recombinant Fragment of an Outer Membrane Protein from a Virulent Strain of Rickettsia prowazekii. Biochimica [0079] 33. Ching W M, Zhang Z, Dasch G A, and Olson J G. Improved diagnosis of typhus rickettsiae using a chemically methylated recombinant s-layer protein fragment. Amer. Soc. Biochem. & Mole. Biol./Amer. Soc. Pham. & Exper. Therap. 2000. Boston, Mass. abstract # 463.

Sequence CWU 1

291710PRTRickettsia typhi 1Met Gly Ala Val Met Gln Tyr Asn Arg Thr Thr Asn Ala Ala Ala Thr1 5 10 15Thr Val Asp Gly Ala Gly Phe Asp Gln Thr Gly Ala Gly Val Asn Leu 20 25 30Pro Val Ala Thr Asn Ser Val Ile Thr Ala Asn Ser Asn Asn Ala Ile 35 40 45Thr Phe Asn Thr Pro Asn Gly Asn Leu Asn Ser Leu Phe Leu Asp Thr 50 55 60Ala Asn Thr Leu Ala Val Thr Ile Asn Glu Asn Thr Thr Leu Gly Phe65 70 75 80Val Thr Asn Val Thr Lys Gln Gly Asn Phe Phe Asn Phe Thr Ile Gly 85 90 95Ala Gly Lys Ser Leu Thr Ile Thr Gly His Gly Ile Thr Ala Gln Gln 100 105 110Ala Ala Thr Thr Lys Ser Ala Gln Asn Val Val Ser Lys Val Asn Ala 115 120 125Gly Ala Ala Ile Asn Asp Asn Asp Leu Ser Gly Val Gly Ser Ile Asp 130 135 140Phe Thr Ala Ala Pro Ser Val Leu Glu Phe Asn Leu Ile Asn Pro Thr145 150 155 160Thr Gln Glu Ala Pro Leu Thr Leu Gly Asp Asn Ala Lys Ile Val Asn 165 170 175Gly Ala Asn Gly Ile Leu Asn Ile Thr Asn Gly Phe Val Lys Val Ser 180 185 190Asp Lys Thr Phe Ala Gly Ile Lys Thr Ile Asn Ile Gly Asp Asn Gln 195 200 205Gly Leu Met Phe Asn Thr Thr Pro Asp Ala Ala Asn Ala Leu Asn Leu 210 215 220Gln Gly Gly Gly Asn Thr Ile Asn Phe Asn Gly Arg Asp Gly Thr Gly225 230 235 240Lys Leu Val Leu Val Ser Lys Asn Gly Asn Ala Thr Glu Phe Asn Val 245 250 255Thr Gly Ser Leu Gly Gly Asn Leu Lys Gly Val Ile Glu Phe Asp Thr 260 265 270Thr Ala Ala Ala Gly Lys Leu Ile Ala Asn Gly Gly Ala Ala Asn Ala 275 280 285Val Ile Gly Thr Asp Asn Gly Ala Gly Arg Ala Ala Gly Phe Ile Val 290 295 300Ser Val Asp Asn Gly Asn Ala Ala Thr Ile Ser Gly Gln Val Tyr Ala305 310 315 320Lys Asp Ile Val Ile Gln Ser Ala Asn Ala Gly Gly Gln Val Thr Phe 325 330 335Glu His Leu Val Asp Val Gly Leu Gly Gly Lys Thr Asn Phe Lys Thr 340 345 350Ala Asp Ser Lys Val Ile Ile Thr Glu Asn Ala Ser Phe Gly Ser Thr 355 360 365Asp Phe Gly Asn Leu Ala Val Gln Ile Val Val Pro Asn Asn Lys Ile 370 375 380Leu Thr Gly Asn Phe Ile Gly Asp Ala Lys Asn Asn Gly Asn Thr Ala385 390 395 400Gly Val Ile Thr Phe Asn Ala Asn Gly Thr Leu Val Ser Gly Asn Thr 405 410 415Asp Pro Asn Ile Val Val Thr Asn Ile Lys Ala Ile Glu Val Glu Gly 420 425 430Ala Gly Ile Val Gln Leu Ser Gly Ile His Gly Ala Glu Leu Arg Leu 435 440 445Gly Asn Ala Gly Ser Ile Phe Lys Leu Ala Asp Gly Thr Val Ile Asn 450 455 460Gly Pro Val Asn Gln Asn Pro Leu Val Asn Asn Asn Ala Leu Ala Ala465 470 475 480Gly Ser Ile Gln Leu Asp Gly Ser Ala Ile Ile Thr Gly Asp Ile Gly 485 490 495Asn Gly Ala Val Asn Ala Ala Leu Gln Asp Ile Thr Leu Ala Asn Asp 500 505 510Ala Ser Lys Ile Leu Thr Leu Ser Gly Ala Asn Ile Ile Gly Ala Asn 515 520 525Ala Gly Gly Ala Ile His Phe Gln Ala Asn Gly Gly Thr Ile Gln Leu 530 535 540Thr Ser Thr Gln Asn Asn Ile Leu Val Asp Phe Asp Leu Asp Val Thr545 550 555 560Thr Asp Gln Thr Gly Val Val Asp Ala Ser Ser Leu Thr Asn Asn Gln 565 570 575Thr Leu Thr Ile Asn Gly Ser Ile Gly Thr Ile Gly Ala Asn Thr Lys 580 585 590Thr Leu Gly Arg Phe Asn Val Gly Ser Ser Lys Thr Ile Leu Asn Ala 595 600 605Gly Asp Val Ala Ile Asn Glu Leu Val Met Glu Asn Asp Gly Ser Val 610 615 620His Leu Thr His Asn Thr Tyr Leu Ile Thr Lys Thr Ile Asn Ala Ala625 630 635 640Asn Gln Gly Lys Ile Ile Val Ala Ala Asp Pro Ile Asn Thr Asp Thr 645 650 655Ala Leu Ala Asp Gly Thr Asn Leu Gly Ser Ala Glu Ser Pro Leu Ser 660 665 670Asn Ile His Phe Ala Thr Lys Ala Ala Asn Gly Asp Ser Ile Leu His 675 680 685Ile Gly Lys Gly Val Asn Leu Tyr Ala Asn Asn Ile Thr Thr Thr Asp 690 695 700Ala Asn Val Gly Ser Leu705 71022130DNARickettsia typhi 2atgggtgctg ttatgcaata taatagaaca acaaatgcag cagctacaac tgttgatggt 60gcaggatttg atcaaactgg cgctggtgtt aatcttcctg tcgctacaaa ttcggttatt 120actgctaatt ctaataatgc tattactttt aatactccaa acggtaattt aaatagtttg 180tttttggata ctgcaaatac tttagcagta acaattaatg aaaatactac cttagggttt 240gtaactaatg ttactaaaca gggtaacttc tttaatttta ctattggtgc tggtaaaagt 300cttaccataa caggtcatgg tattactgct caacaagctg ctactacaaa aagtgctcaa 360aatgttgttt caaaagttaa tgctggtgct gctattaacg ataatgatct tagcggtgta 420ggatcaatag actttactgc tgcgccttct gtattagaat ttaatttaat aaatcctaca 480actcaagaag ctcctcttac acttggtgat aatgctaaaa tagttaatgg tgctaatggg 540atattaaata ttactaatgg gtttgttaag gtttcagata aaacttttgc tggtattaag 600acaattaata tcggtgataa tcaaggttta atgtttaata ctactcctga tgccgctaat 660gctttaaatt tgcaaggagg tggtaatact attaatttta atggaagaga cggtactggt 720aaattagtat tggtcagtaa gaatggcaat gctactgaat ttaatgttac aggaagttta 780ggcggtaatc taaaaggtgt tattgaattt gatactacag cagcagctgg taagcttatc 840gctaatggag gtgctgctaa tgcagtaata ggtacagata atggagcagg tagagctgca 900ggatttattg ttagtgttga taatggtaat gcagcaacaa tttccggaca ggtttatgct 960aaagacatag ttatacaaag tgctaatgca ggtggacaag tcacttttga acatttagtt 1020gatgttggtt taggcggtaa gaccaatttt aaaaccgcag attctaaagt tataataaca 1080gaaaacgcaa gctttggttc tactgatttt ggtaatcttg cagtacagat tgtagtgcct 1140aataataaga tacttacagg taatttcata ggtgatgcaa aaaataacgg taatactgca 1200ggtgtgatca cttttaatgc taatggtact ttagtaagtg gtaatactga tccaaatatt 1260gtagtaacaa atattaaggc aatcgaagta gaaggtgccg ggattgtaca attatcagga 1320atacatggtg cagaattacg tttaggaaat gctggctcta tctttaaact tgctgatggc 1380acagtgatta acggtccagt taaccaaaat cctcttgtga ataataatgc gcttgcagct 1440ggttctattc agttagatgg aagtgctata attaccggtg atataggtaa cggtgctgtt 1500aatgctgcgt tacaagacat tactttagct aatgatgctt caaaaatatt aacacttagt 1560ggggcaaata ttatcggcgc taatgctggt ggtgcaattc attttcaagc taacggtggt 1620actattcaat taacaagcac tcaaaataat attttagttg attttgattt agatgtaact 1680actgatcaaa caggtgttgt tgatgcaagt agtttaacaa ataatcaaac tttaactatt 1740aatggtagca tcggtactat tggcgctaat actaaaacac ttggaagatt taatgttggg 1800tcaagtaaaa caatattaaa tgctggagat gttgctatta acgagttagt tatggaaaat 1860gatggttcag tacaccttac tcacaatact tacttaataa caaaaactat caatgctgca 1920aatcaaggta aaatcatagt tgccgctgat cctattaata ctgatacagc tcttgctgat 1980ggtacgaatt taggtagtgc agaaagtcca ctttctaata ttcattttgc tactaaagct 2040gctaatggtg actctatatt acatataggt aaaggagtaa atttatatgc taataatatt 2100actactaccg atgctaatgt aggttcttaa 21303330PRTRickettsia typhi 3Met Ala Gln Lys Pro Asn Phe Leu Lys Lys Ile Ile Ser Ala Gly Leu1 5 10 15Val Thr Ala Ser Thr Ala Thr Ile Val Ala Gly Phe Ser Gly Val Ala 20 25 30Met Gly Ala Val Met Gln Tyr Asn Arg Thr Thr Asn Ala Ala Ala Thr 35 40 45Thr Val Asp Gly Ala Gly Phe Asp Gln Thr Gly Ala Gly Val Asn Leu 50 55 60Pro Val Ala Thr Asn Ser Val Ile Thr Ala Asn Ser Asn Asn Ala Ile65 70 75 80Thr Phe Asn Thr Pro Asn Gly Asn Leu Asn Ser Leu Phe Leu Asp Thr 85 90 95Ala Asn Thr Leu Ala Val Thr Ile Asn Glu Asn Thr Thr Leu Gly Phe 100 105 110Val Thr Asn Val Thr Lys Gln Gly Asn Phe Phe Asn Phe Thr Ile Gly 115 120 125Ala Gly Lys Ser Leu Thr Ile Thr Gly His Gly Ile Thr Ala Gln Gln 130 135 140Ala Ala Thr Thr Lys Ser Ala Gln Asn Val Val Ser Lys Val Asn Ala145 150 155 160Gly Ala Ala Ile Asn Asp Asn Asp Leu Ser Gly Val Gly Ser Ile Asp 165 170 175Phe Thr Ala Ala Pro Ser Val Leu Glu Phe Asn Leu Ile Asn Pro Thr 180 185 190Thr Gln Glu Ala Pro Leu Thr Leu Gly Asp Asn Ala Lys Ile Val Asn 195 200 205Gly Ala Asn Gly Ile Leu Asn Ile Thr Asn Gly Phe Val Lys Val Ser 210 215 220Asp Lys Thr Phe Ala Gly Ile Lys Thr Ile Asn Ile Gly Asp Asn Gln225 230 235 240Gly Leu Met Phe Asn Thr Thr Pro Asp Ala Ala Asn Ala Leu Asn Leu 245 250 255Gln Gly Gly Gly Asn Thr Ile Asn Phe Asn Gly Arg Asp Gly Thr Gly 260 265 270Lys Leu Val Leu Val Ser Lys Asn Gly Asn Ala Thr Glu Phe Asn Val 275 280 285Thr Gly Ser Leu Gly Gly Asn Leu Lys Gly Val Ile Glu Phe Asp Thr 290 295 300Thr Ala Ala Ala Gly Lys Leu Ile Ala Asn Gly Gly Ala Ala Asn Ala305 310 315 320Val Ile Gly Thr Asp Asn Gly Ala Gly Arg 325 33045258DNARickettsia typhi 4cgacaattag cccgtagttt agaaactatt aaaacaaaat atttaggtta tttccttatc 60aaatgtggga tatcttgact catatttgat taatttgttt taatactaga tactaaattt 120taacttaaat atgggaaaaa attatggctc aaaaaccaaa ttttctaaaa aaaataattt 180ccgcaggatt ggtaactgct tccacggcta ctatagttgc tggtttttct ggtgtagcaa 240tgggtgctgt tatgcaatat aatagaacaa caaatgcagc agctacaact gttgatggtg 300caggatttga tcaaactggc gctggtgtta atcttcctgt cgctacaaat tcggttatta 360ctgctaattc taataatgct attactttta atactccaaa cggtaattta aatagtttgt 420ttttggatac tgcaaatact ttagcagtaa caattaatga aaatactacc ttagggtttg 480taactaatgt tactaaacag ggtaacttct ttaattttac tattggtgct ggtaaaagtc 540ttaccataac aggtcatggt attactgctc aacaagctgc tactacaaaa agtgctcaaa 600atgttgtttc aaaagttaat gctggtgctg ctattaacga taatgatctt agcggtgtag 660gatcaataga ctttactgct gcgccttctg tattagaatt taatttaata aatcctacaa 720ctcaagaagc tcctcttaca cttggtgata atgctaaaat agttaatggt gctaatggga 780tattaaatat tactaatggg tttgttaagg tttcagataa aacttttgct ggtattaaga 840caattaatat cggtgataat caaggtttaa tgtttaatac tactcctgat gccgctaatg 900ctttaaattt gcaaggaggt ggtaatacta ttaattttaa tggaagagac ggtactggta 960aattagtatt ggtcagtaag aatggcaatg ctactgaatt taatgttaca ggaagtttag 1020gcggtaatct aaaaggtgtt attgaatttg atactacagc agcagctggt aagcttatcg 1080ctaatggagg tgctgctaat gcagtaatag gtacagataa tggagcaggt agagctgcag 1140gatttattgt tagtgttgat aatggtaatg cagcaacaat ttccggacag gtttatgcta 1200aagacatagt tatacaaagt gctaatgcag gtggacaagt cacttttgaa catttagttg 1260atgttggttt aggcggtaag accaatttta aaaccgcaga ttctaaagtt ataataacag 1320aaaacgcaag ctttggttct actgattttg gtaatcttgc agtacagatt gtagtgccta 1380ataataagat acttacaggt aatttcatag gtgatgcaaa aaataacggt aatactgcag 1440gtgtgatcac ttttaatgct aatggtactt tagtaagtgg taatactgat ccaaatattg 1500tagtaacaaa tattaaggca atcgaagtag aaggtgccgg gattgtacaa ttatcaggaa 1560tacatggtgc agaattacgt ttaggaaatg ctggctctat ctttaaactt gctgatggca 1620cagtgattaa cggtccagtt aaccaaaatc ctcttgtgaa taataatgcg cttgcagctg 1680gttctattca gttagatgga agtgctataa ttaccggtga tataggtaac ggtgctgtta 1740atgctgcgtt acaagacatt actttagcta atgatgcttc aaaaatatta acacttagtg 1800gggcaaatat tatcggcgct aatgctggtg gtgcaattca ttttcaagct aacggtggta 1860ctattcaatt aacaagcact caaaataata ttttagttga ttttgattta gatgtaacta 1920ctgatcaaac aggtgttgtt gatgcaagta gtttaacaaa taatcaaact ttaactatta 1980atggtagcat cggtactatt ggcgctaata ctaaaacact tggaagattt aatgttgggt 2040caagtaaaac aatattaaat gctggagatg ttgctattaa cgagttagtt atggaaaatg 2100atggttcagt acaccttact cacaatactt acttaataac aaaaactatc aatgctgcaa 2160atcaaggtaa aatcatagtt gccgctgatc ctattaatac tgatacagct cttgctgatg 2220gtacgaattt aggtagtgca gaaagtccac tttctaatat tcattttgct actaaagctg 2280ctaatggtga ctctatatta catataggta aaggagtaaa tttatatgct aataatatta 2340ctactaccga tgctaatgta ggttctttac actttaggtc tggtggaacc agtatagtaa 2400gtggtacagt tggtggacag caaggtctta agcttaataa tttaatatta gataatggta 2460ctactgttaa gtttttaggt gatatcacat ttaatggtgg tactaaaatt gaaggtaaat 2520ctatcttgca aattagcagc aattatatta ctgatcatat tgaatctgct gataatactg 2580gtacattaga atttgttaat actgatccta tcaccgtaac gttaaataaa caaggtgctt 2640attttggtgt tttaaaacaa gtaatggttt ctggtccagg taacatagca tttaatgaga 2700taggtaatgg agttgcacat gctatagcag ttgattccat ttcttttgaa aatgcaagtt 2760taggtgcatc tttattctta cttagtggca ctccattaga tgtgctaaca attaaaagta 2820ccgtaggtaa tggtacagta gataatttta atgctcctat tttagttgta tcaggtattg 2880atagtatgat caataacggt caagttatcg gtgatcaaaa gaatattata gctctatcgc 2940ttggaagtga taacagtatt actgttaatt ctaatacatt atatgcaggt atcagaacta 3000ctaaaactaa tcaaggtact gttacactta gcggtggtat acctaataac cctggtacaa 3060tttatggttt aggtttagag aatggtgatc caaagttaaa gcaagtaacg tttactacag 3120attataacaa cttaggtagt attattgcaa ctaacgtaac aattaatgac gatgtaacac 3180ttactacagg aggtatagcc gggacagatt ttgacggtaa aattactctt ggaagtatta 3240acggtaatgc taatgtaaag tttgttgaca gaacattttc tcatcctaca agtatgattg 3300tttctactaa agctaatcag ggtactgtaa cttatttagg taatgcatta gtcggtaata 3360ttggtagttc agatattcct gtagcttctg ttagatttac tggtaatgat agtggtgtag 3420gattacaagg caatattcac tcacaaaata tagactttgg tacttataac ttaactattt 3480taaattctga tgtaatttta ggcggtggta ctactgctat taatggtgag attgatcttt 3540tgacaaataa tttaatattt gcaaatggta cttcaacatg gggcaataat acctctctta 3600gtacaacatt aaacgtatca aacggtaatg taggtcaaat agttattgct gaaggtgctc 3660aagttaatgc aacaactaca ggaactacaa ccattaaaat acaagataat gctaatgcaa 3720atttcagtgg tacacaaact tatactttaa tccaaggtgg tgccagattt aacggtactt 3780taggagctcc taactttgat gtaacaggaa ataatatttt cgtaaaatat gaattaatac 3840gtgatgcgaa tcaggattat gtgttaacac gtactaacga tgtattaaat gtagttacaa 3900cagctgtagg aaatagtgca attgcaaatg cacctggtgt acatcaaaat attgctatat 3960gcttagaatc aactgataca gcagcttata ataatatgct tttagctaaa gattcttctg 4020atgtcgcaac atttatagga gctattgcta cagatacagg tgctgctgta gctacagtaa 4080acttaaatga tacacaaaaa actcaagatc tacttggtaa taggctaggt gcacttagat 4140atctaagtaa ttctgaaact gctgatgttg gtggatctga aacaggtgca gtatcttcag 4200gtgatgaagc gattgatcaa gtatcttatg gtgtatgggc taaacctttc tataacatcg 4260cagaacaaga taaaaaaggt ggtctagctg gttataaagc aaaaactgct ggtgttgtag 4320ttggtttaga tactctcgct aatgataacc taatgattgg tgcagctatt ggtatcacta 4380aaactgacat aaaacaccaa gattataaaa aaggtgataa aactgatatt aagggtttat 4440ccttctctct atatggtgcc cagcagcttg ttaagaattt ctttgctcaa ggtagtgcaa 4500tatttacctt aaacaaagtc aaaagtaaaa gtcagcgtta cttcttcgat gctaatggta 4560agatgaacaa gcaaattgct gccggtaatt atgataacat aacattcggt ggtaatttaa 4620tgtttggtta tgattataat gcactgcaag gtgtattagt gactccaatg gcagggctta 4680gctacttaaa atcttctaat gaaaactata aagaaactgg tactacagtt gcaaataagc 4740gcattcacag caaatttagt gatagaatcg atttaatagt aggtgctaaa gtaactggta 4800gtgctatgaa tataaatgat attgtgatat atccagaaat tcattctttt gtagtgcaca 4860aagtaaatgg taagctatct aaggctcagt ctatgttaga tggacaaact gctccattta 4920tcagtcagcc tgatagaact gctaaaacat cttataatat aggcttaagt gcaaatataa 4980gatctgatgc taagatggag tatggtatcg gttatgattt taatgctgca agtaaatata 5040ctgcacatca aggtacttta aaagtacgta taaatttcta atcattattg atgagtttag 5100tgagtttata acttgatcaa gaaaaaagcc catttttttt aaactgggct tttttctatt 5160tacttatgta atgaggtctt actgtatacg tagtattgca atcattgata ctaaagtctc 5220tttcattgtc aaagtaatat tcgcaatcta gagaataa 5258532DNARickettsia typhi 5ggtggtcata tgggtgctgt tatgcaatat aa 32634DNARickettsia typhi 6cggaattctt ataaagaacc tacattagca tcgg 3471863DNARickettsia typhi 7atgtctggtg gaaccagtat agtaagtggt acagttggtg gacagcaagg tcttaagctt 60aataatttaa tattagataa tggtactact gttaagtttt taggtgatat cacatttaat 120ggtggtacta aaattgaagg taaatctatc ttgcaaatta gcagcaatta tattactgat 180catattgaat ctgctgataa tactggtaca ttagaatttg ttaatactga tcctatcacc 240gtaacgttaa ataaacaagg tgcttatttt ggtgttttaa aacaagtaat ggtttctggt 300ccaggtaaca tagcatttaa tgagataggt aatggagttg cacatgctat agcagttgat 360tccatttctt ttgaaaatgc aagtttaggt gcatctttat tcttacttag tggcactcca 420ttagatgtgc taacaattaa aagtaccgta ggtaatggta cagtagataa ttttaatgct 480cctattttag ttgtatcagg tattgatagt atgatcaata acggtcaagt tatcggtgat 540caaaagaata ttatagctct atcgcttgga agtgataaca gtattactgt taattctaat 600acattatatg caggtatcag aactactaaa actaatcaag gtactgttac acttagcggt 660ggtataccta ataaccctgg tacaatttat ggtttaggtt tagagaatgg tgatccaaag 720ttaaagcaag taacgtttac tacagattat aacaacttag gtagtattat tgcaactaac 780gtaacaatta atgacgatgt aacacttact acaggaggta tagccgggac agattttgac 840ggtaaaatta ctcttggaag tattaacggt aatgctaatg taaagtttgt tgacagaaca 900ttttctcatc ctacaagtat gattgtttct actaaagcta atcagggtac tgtaacttat 960ttaggtaatg cattagtcgg taatattggt agttcagata ttcctgtagc ttctgttaga 1020tttactggta atgatagtgg

tgtaggatta caaggcaata ttcactcaca aaatatagac 1080tttggtactt ataacttaac tattttaaat tctgatgtaa ttttaggcgg tggtactact 1140gctattaatg gtgagattga tcttttgaca aataatttaa tatttgcaaa tggtacttca 1200acatggggca ataatacctc tcttagtaca acattaaacg tatcaaacgg taatgtaggt 1260caaatagtta ttgctgaagg tgctcaagtt aatgcaacaa ctacaggaac tacaaccatt 1320aaaatacaag ataatgctaa tgcaaatttc agtggtacac aaacttatac tttaatccaa 1380ggtggtgcca gatttaacgg tactttagga gctcctaact ttgatgtaac aggaaataat 1440attttcgtaa aatatgaatt aatacgtgat gcgaatcagg attatgtgtt aacacgtact 1500aacgatgtat taaatgtagt tacaacagct gtaggaaata gtgcaattgc aaatgcacct 1560ggtgtacatc aaaatattgc tatatgctta gaatcaactg atacagcagc ttataataat 1620atgcttttag ctaaagattc ttctgatgtc gcaacattta taggagctat tgctacagat 1680acaggtgctg ctgtagctac agtaaactta aatgatacac aaaaaactca agatctactt 1740ggtaataggc taggtgcact tagatatcta agtaattctg aaactgctga tgttggtgga 1800tctgaaacag gtgcagtatc ttcaggtgat gaagcgattg atcaagtatc ttatggtgta 1860taa 18638607PRTRickettsia typhi 8Met Ser Gly Gly Thr Ser Ile Val Ser Gly Thr Val Gly Gly Gln Gln1 5 10 15Gly Leu Lys Leu Asn Asn Leu Ile Leu Asp Asn Gly Thr Thr Val Lys 20 25 30Phe Leu Gly Asp Ile Thr Phe Asn Gly Gly Thr Lys Ile Glu Gly Lys 35 40 45Ser Ile Leu Gln Ile Ser Ser Asn Tyr Ile Thr Asp His Ile Glu Ser 50 55 60Ala Asp Asn Thr Gly Thr Leu Glu Phe Val Asn Thr Asp Pro Ile Thr65 70 75 80Val Thr Leu Asn Lys Gln Gly Ala Tyr Phe Gly Val Leu Lys Gln Val 85 90 95Met Val Ser Gly Pro Gly Asn Ile Ala Phe Asn Glu Ile Gly Asn Gly 100 105 110Val Ala His Ala Ile Ala Val Asp Ser Ile Ser Phe Glu Asn Ala Ser 115 120 125Leu Gly Ala Ser Leu Phe Leu Leu Ser Gly Thr Pro Leu Asp Val Leu 130 135 140Thr Ile Lys Ser Thr Val Gly Asn Gly Thr Val Asp Asn Phe Asn Ala145 150 155 160Pro Ile Leu Val Val Ser Gly Ile Asp Ser Met Ile Asn Asn Gly Gln 165 170 175Val Ile Gly Asp Gln Lys Asn Ile Ile Ala Leu Ser Leu Gly Ser Asp 180 185 190Asn Ser Ile Thr Val Asn Ser Asn Thr Leu Tyr Ala Gly Ile Arg Thr 195 200 205Thr Lys Thr Asn Gln Gly Thr Val Thr Leu Ser Gly Gly Ile Pro Asn 210 215 220Asn Pro Gly Thr Ile Tyr Gly Leu Gly Leu Glu Asn Gly Asp Pro Lys225 230 235 240Leu Lys Gln Val Thr Phe Thr Thr Asp Tyr Asn Asn Leu Gly Ser Ile 245 250 255Ile Ala Thr Asn Val Thr Ile Asn Asp Asp Val Thr Leu Thr Thr Gly 260 265 270Gly Ile Ala Gly Thr Asp Phe Asp Gly Lys Ile Thr Leu Gly Ser Ile 275 280 285Asn Gly Asn Ala Asn Val Lys Phe Val Asp Arg Thr Phe Ser His Pro 290 295 300Thr Ser Met Ile Val Ser Thr Lys Ala Asn Gln Gly Thr Val Thr Tyr305 310 315 320Leu Gly Asn Ala Leu Val Gly Asn Ile Gly Ser Ser Asp Ile Pro Val 325 330 335Ala Ser Val Arg Phe Thr Gly Asn Asp Ser Gly Val Gly Leu Gln Gly 340 345 350Asn Ile His Ser Gln Asn Ile Asp Phe Gly Thr Tyr Asn Leu Thr Ile 355 360 365Leu Asn Ser Asp Val Ile Leu Gly Gly Gly Thr Thr Ala Ile Asn Gly 370 375 380Glu Ile Asp Leu Leu Thr Asn Asn Leu Ile Phe Ala Asn Gly Thr Ser385 390 395 400Thr Trp Gly Asn Asn Thr Ser Leu Ser Thr Thr Leu Asn Val Ser Asn 405 410 415Gly Asn Val Gly Gln Ile Val Ile Ala Glu Gly Ala Gln Val Asn Ala 420 425 430Thr Thr Thr Gly Thr Thr Thr Ile Lys Ile Gln Asp Asn Ala Asn Ala 435 440 445Asn Phe Ser Gly Thr Gln Thr Tyr Thr Leu Ile Gln Gly Gly Ala Arg 450 455 460Phe Asn Gly Thr Leu Gly Ala Pro Asn Phe Asp Val Thr Gly Asn Asn465 470 475 480Ile Phe Val Lys Tyr Glu Leu Ile Arg Asp Ala Asn Gln Asp Tyr Val 485 490 495Leu Thr Arg Thr Asn Asp Val Leu Asn Val Val Thr Thr Ala Val Gly 500 505 510Asn Ser Ala Ile Ala Asn Ala Pro Gly Val His Gln Asn Ile Ala Ile 515 520 525Cys Leu Glu Ser Thr Asp Thr Ala Ala Tyr Asn Asn Met Leu Leu Ala 530 535 540Lys Asp Ser Ser Asp Val Ala Thr Phe Ile Gly Ala Ile Ala Thr Asp545 550 555 560Thr Gly Ala Ala Val Ala Thr Val Asn Leu Asn Asp Thr Gln Lys Thr 565 570 575Gln Asp Leu Leu Gly Asn Arg Leu Gly Ala Leu Arg Tyr Leu Ser Asn 580 585 590Ser Glu Thr Ala Asp Val Gly Gly Ser Glu Thr Gly Ala Val Ser 595 600 605911PRTRickettsia typhi 9Val Met Gln Tyr Asn Arg Thr Thr Asn Ala Ala1 5 101020PRTRickettsia typhi 10Ile Thr Ala Asn Ser Asn Asn Ala Ile Thr Phe Asn Thr Pro Asn Gly1 5 10 15Asn Leu Asn Ser 20118PRTRickettsia typhi 11Thr Asn Val Thr Lys Gln Gly Asn1 51212PRTRickettsia typhi 12Gln Gln Ala Ala Thr Thr Lys Ser Ala Gln Asn Val1 5 10139PRTRickettsia typhi 13Ala Ile Asn Asp Asn Asp Leu Ser Gly1 5149PRTRickettsia typhi 14Ile Asn Pro Thr Thr Gln Glu Ala Pro1 51510PRTRickettsia typhi 15Gly Phe Val Lys Val Ser Asp Lys Thr Phe1 5 101623PRTRickettsia typhi 16Ile Asn Phe Asn Gly Arg Asp Gly Thr Gly Lys Leu Val Leu Val Ser1 5 10 15Lys Asn Gly Asn Ala Thr Glu 20179PRTRickettsia typhi 17Ser Val Asp Asn Gly Asn Ala Ala Thr1 51813PRTRickettsia typhi 18Gly Gly Lys Thr Asn Phe Lys Thr Ala Asp Ser Lys Val1 5 101912PRTRickettsia typhi 19Ile Gly Asp Ala Lys Asn Asn Gly Asn Thr Ala Gly1 5 102010PRTRickettsia typhi 20Thr Leu Val Ser Gly Asn Thr Asp Pro Asn1 5 102116PRTRickettsia typhi 21Asn Gly Pro Val Asn Gln Asn Pro Leu Val Asn Asn Asn Ala Leu Ala1 5 10 152211PRTRickettsia typhi 22Ile Gln Leu Thr Ser Thr Gln Asn Asn Ile Leu1 5 10239PRTRickettsia typhi 23Asp Val Thr Thr Asp Gln Thr Gly Val1 52410PRTRickettsia typhi 24Ser Ser Leu Thr Asn Asn Gln Thr Leu Thr1 5 102515PRTRickettsia typhi 25Asn Thr Lys Thr Leu Gly Arg Phe Asn Val Gly Ser Ser Lys Thr1 5 10 152613PRTRickettsia typhi 26Glu Asn Asp Gly Ser Val His Leu Thr His Asn Thr Tyr1 5 10277PRTRickettsia typhi 27Asn Ala Ala Asn Gln Gly Lys1 5287PRTRickettsia typhi 28Asp Pro Ile Asn Thr Asp Thr1 52913PRTRickettsia typhi 29Asn Asn Ile Thr Thr Thr Asp Ala Asn Val Gly Ser Leu1 5 10

Claims

1. An immunogenic composition comprising the recombinant Rickettsia typhi OmpB polypeptide AN, or fragments thereof, with the amino acid sequence of SEQ ID No. 1.

2. The immunogenic composition of claim 1, wherein said fragments is one or more AN polypeptides with a sequences containing predicted B cell epitopes selected from the group consisting of SEQ ID No. 9-29.

3. A method of detecting R. typhi infection comprising the steps: a. exposing the composition of claim 1 to patient sera; b. measuring antibody bound to said AN polypeptide.

4. The method of claim 2, wherein said composition is immobilized onto a solid surface.

5. The method of claim 2, wherein said method also includes the steps exposing patient sera to recombinant OmpB polypeptide and measuring antibody bound to said OmpB polypeptide.

6. A method for inducing an immune response to R. typhi comprising the steps: a. administering an immunogenic composition comprising the composition of claim 1 in a unit dose range of 50 μg to 2 mg; b. administration of boosting dose of said immunogenic composition at least 1 week after priming dose with unit dose range of 50 μg to 2 mg in a buffered aqueous solution, wherein an immune response is elicited.

7. The method of claim 6, wherein said fragments is one or more AN polypeptides with a sequence containing predicted B cell epitopes selected from the group consisting of SEQ ID No. 9-29.

Images